VMI
LPCN icon

VHCP Management II’s Lipocine LPCN Stock Holding History

VHCP Management II’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-22,760
Closed -$1.33M – 19
2017
Q4 		$1.33M Hold
22,760
– – 0.32% 18
2017
Q3 		$1.54M Hold
22,760
– – 0.42% 15
2017
Q2 		$1.55M Sell
22,760
-1,946
-8% -$127K 0.62% 15
2017
Q1 		$1.64M Hold
24,706
– – 0.67% 15
2016
Q4 		$1.55M Hold
24,706
– – 0.74% 18
2016
Q3 		$1.87M Hold
24,706
– – 0.96% 21
2016
Q2 		$1.28M Hold
24,706
– – 0.77% 20
2016
Q1 		$4.26M Hold
24,706
– – 2.8% 13
2015
Q4 		$5.43M Buy
+24,706
New +$5.18M 4.46% 8

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

VHCP Management II's LPCN Position: Q1 2018 in Review

VHCP Management II sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 22,760 shares — an estimated $1.33M sold.

VHCP Management II first reported a position in LPCN in Q4 2015 and held it in 9 quarters. The position peaked at $5.43M in Q4 2015. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • VHCP Management II reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • VHCP Management II sold 22,760 Lipocine shares in Q1 2018, an estimated $1.33M.
  • VHCP Management II first reported a position in Lipocine in Q4 2015 and held it in 9 quarters.
  • VHCP Management II's Lipocine position peaked at $5.43M in Q4 2015.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on VHCP Management II's 13F filing for Q1 2018, filed 14 May 2018.